Plutux

Healthcare

Trial data, approvals, and what they are worth

Readouts, FDA decisions, drug pricing and payer behaviour, sized in revenue rather than in press-release adjectives.

What Big Funds Own22 fundsWhat Berkshire, Bridgewater and other big funds reported holding last quarter.What Analysts Expect16 stocksRatings and price targets from the big institutions, each with its public source.

2026-08-03

Eli Lilly's “cancer win” narrows the addressable audience—and that’s the real 2027 oncology TAM reset insight cover
Earnings
LLY · BMY•7 min read

Eli Lilly's “cancer win” narrows the addressable audience—and that’s the real 2027 oncology TAM reset

Lilly’s latest oncology positive readout is a genuine efficacy win, but it’s tethered to a biomarker-defined subgroup (RET fusion–positive NSCLC), which shrinks commercial TAM versus “all-comers.” That subgroup math forces a sharper rerate framework for Eli Lilly, changes the opportunity-cost lens on Bristol-Myers Squibb, and matters disproportionately for smaller targeted-oncology platforms like Arvinas and Black Diamond Therapeutics.

Lilly revenue (TTM): $72.25BLilly net income (TTM): $25.28B
Read article
Novo Nordisk ‘claws back’ into obesity because the market is shifting from injections-only to pills-and-next-gen demand insight cover
Industry News
NVO · LLY•8 min read

Novo Nordisk ‘claws back’ into obesity because the market is shifting from injections-only to pills-and-next-gen demand

Novo Nordisk’s obesity narrative is being re-rated around oral GLP-1 execution (including Wegovy pills) rather than only injection leadership—exactly the demand shift that can loosen Lilly’s pricing power. The setup matters because Eli Lilly still trades like a monopoly ($40.8x trailing P/E), while the Reuters-driven “pipeline reset” forces investors to price a wider share of the obesity wallet into Novo’s future.

Novo Nordisk trailing P/E: 11.21xEli Lilly trailing P/E: 40.81x
Read article

2026-08-02

Moderna Cleared the Science Test; August 5 Will Price the Policy Test insight cover
Earnings
MRNA · BNTX•12 min read

Moderna Cleared the Science Test; August 5 Will Price the Policy Test

Moderna's mFlusiva produced 26.6% relative efficacy over a standard flu shot and won unanimous FDA-adviser support, but approval is no longer the only hurdle. HHS has terminated 22 mRNA investments worth nearly $500 million, making recommendation, distribution and uptake the harder tests for Moderna—and the more important read-through for BioNTech and Pfizer.

FDA deadline: Aug. 5Advisory vote: 9–0
Read article

2026-08-01

Replimune Just Doubled After a 10-3 Vote — That's Not the Story. The Story Is That Two FDA Rejections Just Became One Approval insight cover
Earnings
REPL · CAPR•13 min read

Replimune Just Doubled After a 10-3 Vote — That's Not the Story. The Story Is That Two FDA Rejections Just Became One Approval

An FDA panel voted 10-3 on July 30, 2026, that Replimune Group's twice-rejected RP1+nivolumab data were 'evaluable and clinically meaningful,' sending shares up ~128% premarket to $12.44 against a ~$5.41 close. The PDUFA date is August 2, 2026, with the panel win coming one day after the same committee voted 9-3 against Capricor's deramiocel — proving that 2026 adcom outcomes now split cleanly on trial design, not on ideological FDA priors. The deeper read: Vinay Prasad is gone, Marty Makary is out, and the agency is being run by an acting commissioner who has not yet telegraphed a stance, which paradoxically raises the floor on biotech downside-skew bets.

CTGTAC vote (RP1 efficacy): 10-3REPL premarket move: +~128%
Read article
The UFLPA’s 43-Company Expansion Turns Supply-Chain Proof Into a Cross-Industry Cost insight cover
Policy Trade
15 min read

The UFLPA’s 43-Company Expansion Turns Supply-Chain Proof Into a Cross-Industry Cost

DHS added 43 China-based companies to the UFLPA Entity List on July 31, bringing the total to 187 and making the restriction materially broader than an apparel-only issue. The immediate risk is not a blanket tariff: it is shipment detention, denied entry, supplier replacement and documentation costs for importers using aluminum, metals, battery materials, food or electronics linked to the listed entities.

New entities: 43Consolidated list: 187
Read article
Retail Captures the GLP-1 Script: Walmart, Costco, and Amazon Siphon $14B of High-Margin Cash-Pay From PBMs insight cover
Industry News
WMT · COST•14 min read

Retail Captures the GLP-1 Script: Walmart, Costco, and Amazon Siphon $14B of High-Margin Cash-Pay From PBMs

Three retailers — Walmart, Costco, and Amazon — now dispense oral GLP-1s from $25 insured and $149 cash-pay, while the July 1 Medicare GLP-1 Bridge sends $50 scripts through their counters just as 10% of large employers drop coverage for 2027. The shift reroutes billions in rebate-eligible prescriptions around CVS Health Caremark and UnitedHealth OptumRx, and forces independent and chain pharmacies like Walgreens to fill GLP-1s at a loss. The structural read-through: branded volumes to Eli Lilly and Novo Nordisk hold up, but PBM rebate economics, telehealth disruptors like Hims & Hers, and price-discovery platforms like GoodRx all lose pricing power and per-script margin simultaneously.

Event Date: 2026-08-01Topic Type: Industry News
Read article

2026-07-31

Novo's ZEUS Heart-Drug Flop Doesn't Kill the GLP-1 Trade — It Redraws the Obesity Stack's Power Lines insight cover
Industry News
NVO · LLY•15 min read

Novo's ZEUS Heart-Drug Flop Doesn't Kill the GLP-1 Trade — It Redraws the Obesity Stack's Power Lines

Novo Nordisk lost ~$30B in market cap Friday after ziltivekimab — an anti-IL-6 antibody, not a GLP-1 — flunked its 6,300-patient ZEUS cardiovascular outcomes trial with a hazard ratio of 0.99. The bigger story is what the failure reveals: the cardiovascular label is going to be won by GLP-1 mechanism drugs (where Eli Lilly already owns the SUMMIT HFpEF data), not by anti-inflammatory add-ons. With HERMES and ARTEMIS still reading out in H1 2027, the GLP-1 trade pivots from TAM to indication-by-indication — and the supply chain that picks up the slack is concentrated in three US wholesalers and a few CDMO champions.

Novo Nordisk trailing P/E: 12.2xEli Lilly trailing P/E: 42.9x
Read article

2026-07-30

Haleon’s H1 “US slip / Oral Health win” reframes the staples trade into a category bet insight cover
Earnings
8 min read

Haleon’s H1 “US slip / Oral Health win” reframes the staples trade into a category bet

Haleon reaffirmed full-year guidance, but H1’s internal split matters: Oral Health delivered mid-single-digit growth while North America slowed versus stronger Emerging Markets. For investors running “premium staples” pair trades, the earnings print shifts the question from “staples resilience” to “which category compounds when the US consumer softens.”

H1 2026 organic revenue: 2.6%H1 2026 revenue: £5,602m
Read article
Johnson & Johnson's FY2026 EPS guide drops ~5% on deal/integration costs—proof the pharma M&A cycle is now a P&L story insight cover
Earnings
JNJ•7 min read

Johnson & Johnson's FY2026 EPS guide drops ~5% on deal/integration costs—proof the pharma M&A cycle is now a P&L story

After beating in Q2, Johnson & Johnson still cut FY2026 adjusted EPS guidance to $10.96–$11.11, attributing the reset to integration/transaction costs. The signal is broader than one quarter: the 2026–2027 healthcare earnings template is shifting from “pipeline-shaped upside” to “M&A-shaped near-term earnings pressure,” with investors needing to separate one-time deal costs from underlying franchise health.

FY2026 adjusted EPS (new guide): $10.96–$11.11FY2026 adjusted EPS (prior guide): $11.60–$11.75
Read article

2026-07-29

Boston Scientific bets on cost cuts as WATCHMAN mix risk rises—how to separate restructuring alpha from franchise dilution insight cover
Earnings
BSX•9 min read

Boston Scientific bets on cost cuts as WATCHMAN mix risk rises—how to separate restructuring alpha from franchise dilution

Boston Scientific’s cost-savings program targets ~$500M annual expense reduction after a $700M–$800M charge window, but it comes while management flagged a 2026 headwind tied to Watchman stand-alone procedure usage. Investors should track whether restructuring-generated operating leverage can offset a shift from “stand-alone” to “bundled” cardiac workflows that can compress product-mix value per procedure at the margin.

Restructuring plan approval date: Jul 21, 2026Expected pre-tax restructuring charges: $700M–$800M
Read article
FTC’s Hims & Hers Pixel Case Makes Meta and Snap the Real Compliance Bottleneck for Telehealth PHI Advertising insight cover
Industry News
META · SNAP•8 min read

FTC’s Hims & Hers Pixel Case Makes Meta and Snap the Real Compliance Bottleneck for Telehealth PHI Advertising

The FTC (with LA County and Utah) alleges Hims & Hers sent sensitive health data to Meta and Snap pixel tracking systems used for ad targeting/measurement. The key shift for investors is that the “HIPAA pixel loophole” becomes a de facto gatekeeping constraint on the entire consumer-telehealth ad-tech stack—raising compliance, remediation, and potential usage-cost risks for Meta META and Snap SNAP alongside the advertiser.

Hims & Hers Health, Inc. FY revenue: $2.35BHims & Hers Health, Inc. FY net income: $0.13B
Read article

2026-07-28

Boston Scientific’s $700–800M restructuring is a multi-year operating-leverage bet: the $500M annualized savings math has to land by 2029 insight cover
Earnings
BSX•8 min read

Boston Scientific’s $700–800M restructuring is a multi-year operating-leverage bet: the $500M annualized savings math has to land by 2029

Boston Scientific BSX approved a 2026–2029 restructuring with ~$700–$800M of pre-tax charges and ~$500M of annualized gross expense reduction, including ~$600–$700M in future cash outlays. The strategic read-through is that this is meant to reconfigure manufacturing and supply-chain footprint for margin expansion—not just cut costs—so 2027 peer comparisons will hinge on how much of the savings the company actually realizes versus the one-time spend.

FY revenue (baseline): $20.1BOperating income (baseline): $4.0B
Read article
GSK's $2.5B savings drive is really a pipeline-reliability budget—so the market should price its R&D conversions, not just “patent cliff” cuts insight cover
Industry News
GSK•7 min read

GSK's $2.5B savings drive is really a pipeline-reliability budget—so the market should price its R&D conversions, not just “patent cliff” cuts

GSK’s announced cost-savings drive is framed as funding its pipeline by improving R&D productivity and execution timing, not merely extending cash via patent protection. That shifts the reinvestment math: investors should watch whether pipeline risk-adjacent value is rising fast enough to justify sustained R&D spend and commercial intensity.

FY2025 revenue: £32.7BFY2025 R&D expense: £7.5B
Read article
J&J’s $5.5B talc settlement is the end of the overhang—but only if the third-party class actually gets funded insight cover
Earnings
8 min read

J&J’s $5.5B talc settlement is the end of the overhang—but only if the third-party class actually gets funded

Johnson & Johnson’s most recent talc resolution step removes a chunk of remaining litigation accounting risk, but the real investor question is structural: what entity funds the third-party claimant class and at what participation rate. J&J’s filings show it still carries a remaining talc balance (~$3.7B as of 2Q26), so the “$5.5B close” narrative only fully de-risks the stock if the class funding mechanism performs as promised.

FY2025 revenue: $94.19BFY2025 operating income: $25.60B
Read article

2026-07-27

Brain-to-Robot Interfaces Won’t Win on Models—They’ll Win on the Sensor-to-Edge Stack insight cover
Industry News
7 min read

Brain-to-Robot Interfaces Won’t Win on Models—They’ll Win on the Sensor-to-Edge Stack

For physical AI, the key shift from “camera + commands” to “neural intent” creates a new bottleneck: who controls the real-time sensor decoding chain and edge compute that turns EEG/BCI signals into robot-safe actions. The investable winners are likely the listed edge-compute and low-latency interface infrastructure providers, but the exact public financial linkage is not yet fully verifiable from primary sources in this run.

Event Date: 2026-07-27Topic Type: Industry News
Read article
Capricor’s Duchenne BLA is back on track—but the FDA’s remaining uncertainty is what investors should price insight cover
Earnings
7 min read

Capricor’s Duchenne BLA is back on track—but the FDA’s remaining uncertainty is what investors should price

Capricor’s Duchenne cell-therapy program avoided a dead end when the FDA resumed BLA review and set an Aug. 22, 2026 PDUFA action date after earlier rejection. But the “fix” was not another full clinical re-run; it was an FDA request for complete study reporting—meaning the approval-path durability still hinges on regulator confidence, not just trial headlines.

Event Date: 2026-07-27Topic Type: Earnings
Read article

2026-07-26

Biosecurity compliance becomes the AI moat: the “perimeter” stack will determine who can ship frontier models into regulated use insight cover
Industry News
MSFT · GOOGL•9 min read

Biosecurity compliance becomes the AI moat: the “perimeter” stack will determine who can ship frontier models into regulated use

Verified public policy momentum is shifting frontier AI from “safety optional” to regulated dual-use governance—starting with biosecurity testing and extending into synthetic DNA/RNA screening. Investors should focus less on generic AI safety and more on the firms that can build, audit, and operate the compliance perimeter (evaluation, logging, and identity-aware controls) that governments and enterprises will require.

Microsoft revenue scale (latest TTM): $318.3BAlphabet revenue scale (latest TTM): $445.9B
Read article

2026-07-25

FDA’s Split Vote Points to a Winner-Take-Most Compounding Market for Six Peptides—If Safety and Sourcing Controls Stay the Barrier insight cover
Industry News
9 min read

FDA’s Split Vote Points to a Winner-Take-Most Compounding Market for Six Peptides—If Safety and Sourcing Controls Stay the Barrier

The FDA’s Pharmacy Compounding Advisory Committee (PCAC) reviewed seven unapproved peptides for potential inclusion on the 503A Bulks List during July 23–24, 2026, with a narrow split that effectively grants a “six-peptide opening” rather than an all-clear. For investors, the real battleground is not demand; it’s who can operationalize compliant sourcing, manufacturing disclosure discipline, and telehealth-adjacent marketing risk controls without running afoul of FDA enforcement.

Adcomm decision format: Non-bindingPeptides reviewed: 7
Read article

2026-07-24

AstraZeneca's Wainua Flop Cuts Deeper Than the Trial Itself — A Second Late-Stage Miss in Ten Weeks Just Repriced the Pipeline insight cover
Earnings
AZN · IONS•12 min read

AstraZeneca's Wainua Flop Cuts Deeper Than the Trial Itself — A Second Late-Stage Miss in Ten Weeks Just Repriced the Pipeline

AstraZeneca's CARDIO-TTRansform readout on July 9, 2026 wiped ~$24B in market value on a trial analysts said removed only 2-4% from fair value — because it landed ten weeks after the camizestrant adcomm blowup, and forced investors to question whether the $80B 2030 plan can absorb two more high-risk readouts in H2 2026. The pipeline premium, not the missing $5B in peak sales, is what's on sale; Ionis took the partner hit (-21%), while BridgeBio and Alnylam inherit the ATTR-CM monopoly Pfizer once owned.

AZN share drop (July 9, 2026): −9%Market value erased: ~$24B
Read article

2026-07-23

UnitedHealth Isn’t Just Timing the Medicare Advantage Turn—Its Medical-Care Ratio Disappearing Gap Sets Up the Elevance “Peer-League” Test insight cover
Industry News
UNH · ELV•8 min read

UnitedHealth Isn’t Just Timing the Medicare Advantage Turn—Its Medical-Care Ratio Disappearing Gap Sets Up the Elevance “Peer-League” Test

In UnitedHealth’s SEC filings, the Medical Care Ratio (MCR) moved from 85.5% (2024) to 89.1% (2025), then improved in early 2026 (83.9% in Q1’26). The falsifiable sector thesis for investors is whether that discipline shows up in Elevance Health’s reported Medicare Advantage medical-cost trend and risk-adjustment outcomes as CMS accelerates RADV audits—turning “recovery” into a measurable peer-league pattern rather than UNH-specific timing.

UnitedHealth TTM revenue (approx., from d: $450.1BUnitedHealth TTM net income (approx., dat: $14.1B
Read article

What to expect

Evidence-first notes with a visible point of view.

This section collects sharp takes on earnings, shareholder meetings, and market structure. Each new piece should make the thesis, the facts, and the implications obvious within the first few screens.

Expect direct analysis, not generic commentary.

Expect the data to be explicit and the argument to be easy to follow.

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

© Plutux Technology Limited 2026